Cargando…

Application of dynamic modeling for survival estimation in advanced renal cell carcinoma

OBJECTIVE: In oncology, extrapolation of clinical outcomes beyond trial duration is traditionally achieved by parametric survival analysis using population-level outcomes. This approach may not fully capture the benefit/risk profile of immunotherapies due to their unique mechanisms of action. We eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deniz, Baris, Altincatal, Arman, Ambavane, Apoorva, Rao, Sumati, Doan, Justin, Malcolm, Bill, Michaelson, M. Dror, Yang, Shuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117067/ https://www.ncbi.nlm.nih.gov/pubmed/30161244 http://dx.doi.org/10.1371/journal.pone.0203406

Ejemplares similares

Treatment sequences for advanced renal cell carcinoma: A health economic assessment
por: Deniz, Baris, et al.
Publicado: (2019)

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
por: Lanitis, Tereza, et al.
Publicado: (2019)

2814. The Impact of Novel Antibiotics on Curbing Antimicrobial Resistance and Infection Spread a Dynamic Modeling Study
por: Ambavane, Apoorva, et al.
Publicado: (2023)

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
por: McCrea, Charles, et al.
Publicado: (2018)

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
por: Gao, Xin, et al.
Publicado: (2019)

Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
por: Lawson, Richard, et al.
Publicado: (2016)

Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes
por: Smare, Caitlin, et al.
Publicado: (2019)

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
por: Shah, Anshul, et al.
Publicado: (2021)

Associations Between Timeliness of Therapy and Clinical and Economic Outcomes Among Patients With Serious Infections Due to Gram-negative Bacteria (GNB): How Much Does Delayed Appropriate Therapy (DAT) Matter?
por: Bonine, Nicole G, et al.
Publicado: (2017)

Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae?
por: Lodise, Thomas, et al.
Publicado: (2017)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate
por: Scott, Thomas F., et al.
Publicado: (2021)

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps
por: Guo, Shien, et al.
Publicado: (2012)

Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening
por: Phillips, Glenn A, et al.
Publicado: (2014)

Antimicrobial Resistance or Delayed Appropriate Therapy—Does One Influence Outcomes More Than the Other Among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?
por: Lodise, Thomas P, et al.
Publicado: (2019)

Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department
por: Ambavane, Apoorva, et al.
Publicado: (2017)

Correction: Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department
por: Ambavane, Apoorva, et al.
Publicado: (2018)

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
por: Choueiri, Toni K., et al.
Publicado: (2018)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Dementia Coding, Workup, and Treatment in the VA New England Healthcare System
por: Cho, Kelly, et al.
Publicado: (2014)

Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset
por: Waterhouse, David, et al.
Publicado: (2021)

The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma
por: Shafrin, Jason, et al.
Publicado: (2017)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
por: George, Daniel J., et al.
Publicado: (2019)

TiSAn: estimating tissue-specific effects of coding and non-coding variants
por: Vervier, Kévin, et al.
Publicado: (2018)

Dynamic estimates of survival in oncocytic cell carcinoma of the thyroid
por: Shi, Yang, et al.
Publicado: (2023)

Advances in survival analysis
por: Rao, C R, et al.
Publicado: (2004)

Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma
por: Liu, Jun S., et al.
Publicado: (2016)

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
por: Molina, Ana M., et al.
Publicado: (2013)

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2
por: Gill, David M, et al.
Publicado: (2016)

Accuracy of oncologists’ estimates of expected survival time in advanced cancer
por: Nahm, Sharon H, et al.
Publicado: (2023)

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
por: DePrimo, Samuel E, et al.
Publicado: (2007)

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]
por: Choueiri, Toni K., et al.
Publicado: (2018)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics
por: Hersh, Carrie M, et al.
Publicado: (2022)

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
por: Patil, S, et al.
Publicado: (2012)

Interplay of polyethyleneimine molecular weight and oligonucleotide backbone chemistry in the dynamics of antisense activity
por: Sundaram, Sumati, et al.
Publicado: (2007)

Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab
por: Shao, Ning, et al.
Publicado: (2019)

Estimating the optimal entry point of the antegrade femoral nailing: Previous and novel morphometric measurements
por: Erçakmak Güneş, Burcu, et al.
Publicado: (2022)

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
por: Corren, Jonathan, et al.
Publicado: (2023)

The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective
por: Menzin, Joseph, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7rmv6kbg4gaimenr0abv5omttp